Tomoko Smyth

1.0k total citations
33 papers, 631 citations indexed

About

Tomoko Smyth is a scholar working on Molecular Biology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tomoko Smyth has authored 33 papers receiving a total of 631 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 12 papers in Immunology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tomoko Smyth's work include Ubiquitin and proteasome pathways (7 papers), Heat shock proteins research (7 papers) and ATP Synthase and ATPases Research (5 papers). Tomoko Smyth is often cited by papers focused on Ubiquitin and proteasome pathways (7 papers), Heat shock proteins research (7 papers) and ATP Synthase and ATPases Research (5 papers). Tomoko Smyth collaborates with scholars based in United Kingdom, United States and Japan. Tomoko Smyth's co-authors include John F. Lyons, Neil T. Thompson, Nicola G. Wallis, Clare Bryant, Jayne Curry, Duncan J. Maskell, Tom P. Monie, Trevelyan J. McKinley, Monique Gangloff and Nicholas J. Gay and has published in prestigious journals such as Blood, The Journal of Immunology and Cancer Research.

In The Last Decade

Tomoko Smyth

31 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomoko Smyth United Kingdom 12 376 202 159 89 86 33 631
Trevor Clancy Norway 18 439 1.2× 358 1.8× 326 2.1× 56 0.6× 95 1.1× 37 891
Huihua Zhang China 14 322 0.9× 151 0.7× 363 2.3× 45 0.5× 105 1.2× 38 757
Dan Su United States 16 517 1.4× 101 0.5× 246 1.5× 57 0.6× 53 0.6× 42 719
Ami Miller United Kingdom 12 433 1.2× 196 1.0× 143 0.9× 58 0.7× 31 0.4× 23 747
Tuhina Mazumdar United States 17 398 1.1× 143 0.7× 232 1.5× 71 0.8× 104 1.2× 32 785
Ciara Ryan Ireland 11 442 1.2× 77 0.4× 178 1.1× 56 0.6× 48 0.6× 29 750
Angus D. Cowan Australia 9 702 1.9× 157 0.8× 193 1.2× 76 0.9× 56 0.7× 11 890
Judith Gan Israel 10 404 1.1× 290 1.4× 201 1.3× 67 0.8× 54 0.6× 13 774
Yanping Yu United States 16 627 1.7× 124 0.6× 118 0.7× 68 0.8× 68 0.8× 33 883
Shannon Telesco United States 13 507 1.3× 125 0.6× 350 2.2× 58 0.7× 102 1.2× 29 985

Countries citing papers authored by Tomoko Smyth

Since Specialization
Citations

This map shows the geographic impact of Tomoko Smyth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoko Smyth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoko Smyth more than expected).

Fields of papers citing papers by Tomoko Smyth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoko Smyth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoko Smyth. The network helps show where Tomoko Smyth may publish in the future.

Co-authorship network of co-authors of Tomoko Smyth

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoko Smyth. A scholar is included among the top collaborators of Tomoko Smyth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoko Smyth. Tomoko Smyth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sims, Martin, et al.. (2025). The IAP antagonist tolinapant enhances the anti-tumor activity of cell therapies. European Journal of Pharmacology. 995. 177400–177400.
2.
Ward, George A., Zhiqiang Zhang, Simone Jueliger, et al.. (2024). Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. Cancer Research Communications. 4(6). 1441–1453. 2 indexed citations
3.
Crawford, Nyree, Tamas Sessler, Christopher McCann, et al.. (2021). Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. Molecular Cancer Therapeutics. 20(9). 1627–1639. 21 indexed citations
4.
Ferrari, Nicola, George A. Ward, Christina Gewinner, et al.. (2021). Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Advances. 5(20). 4003–4016. 5 indexed citations
5.
Khanh, T., Geraldine O’Sullivan Coyne, John L. Hays, et al.. (2020). Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 86(6). 815–827. 18 indexed citations
6.
Ward, George A., Edward J. Lewis, Jong Sook Ahn, et al.. (2018). ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Molecular Cancer Therapeutics. 17(7). 1381–1391. 53 indexed citations
7.
Courtin, Aurélie, Tomoko Smyth, Keisha Hearn, et al.. (2016). Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib. British Journal of Cancer. 115(9). 1069–1077. 23 indexed citations
8.
Smyth, Tomoko, Yoko Nakatsuru, George A. Ward, et al.. (2016). Abstract 1287: The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo. Cancer Research. 76(14_Supplement). 1287–1287. 1 indexed citations
9.
Chan, Pui Shan, Kwok Wai Lo, Jayne Curry, et al.. (2013). A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Molecular Cancer. 12(1). 128–128. 53 indexed citations
10.
Smyth, Tomoko, Thomas Van Looy, Jayne Curry, et al.. (2012). The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models. Molecular Cancer Therapeutics. 11(8). 1799–1808. 49 indexed citations
11.
Graham, Brent, Jayne Curry, Tomoko Smyth, et al.. (2011). The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer. Cancer Science. 103(3). 522–527. 65 indexed citations
12.
Smyth, Tomoko, Thomas Van Looy, Jayne Curry, et al.. (2011). Abstract A217: The HSP90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor models.. Molecular Cancer Therapeutics. 10(11_Supplement). A217–A217.
13.
Dawson, Mark A., Jayne Curry, Philip Beer, et al.. (2010). AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. British Journal of Haematology. 150(1). 46–57. 41 indexed citations
14.
Tanaka, Ruriko, Matthew Squires, Shinya Kimura, et al.. (2010). Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells. Blood. 116(12). 2089–2095. 56 indexed citations
15.
Lyons, John, Jayne Curry, Tomoko Smyth, et al.. (2009). Abstract A217: Comparison of long-term pharmacodynamic actions of the synthetic small molecule HSP90 inhibitor AT13387 in multiple xenograft models. Molecular Cancer Therapeutics. 8(12_Supplement). A217–A217. 2 indexed citations
16.
Walsh, Catharine M., Monique Gangloff, Tom P. Monie, et al.. (2008). Elucidation of the MD-2/TLR4 Interface Required for Signaling by Lipid IVa. The Journal of Immunology. 181(2). 1245–1254. 110 indexed citations
17.
Smyth, Tomoko, et al.. (2008). Dexamethasone modulatesSalmonella entericaserovar Typhimurium infectionin vivoindependently of the glucocorticoid-inducible protein annexin-A1. FEMS Immunology & Medical Microbiology. 54(3). 339–348. 8 indexed citations
18.
Tanaka, Ruriko, Matthew Squires, Shinya Kimura, et al.. (2008). Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.. Blood. 112(11). 1104–1104. 6 indexed citations
19.
Bull, Sarah, J. C. Vendrig, Tomoko Smyth, et al.. (2006). Genotyping of Toll-like receptor 4, myeloid differentiation factor 2 and CD-14 in the horse: An investigation into the influence of genetic polymorphisms on the LPS induced TNF-α response in equine whole blood. Veterinary Immunology and Immunopathology. 111(3-4). 165–173. 19 indexed citations
20.
Smyth, Tomoko, Hayley J. Harris, Andy Brown, et al.. (2005). Differential modulatory effects of Annexin 1 on nitric oxide synthase induction by lipopolysaccharide in macrophages. Immunology. 117(3). 340–349. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Trevor Clancy Breakdown of academic impact, for papers by Huihua Zhang Breakdown of academic impact, for papers by Dan Su Breakdown of academic impact, for papers by Ami Miller Breakdown of academic impact, for papers by Tuhina Mazumdar Breakdown of academic impact, for papers by Ciara Ryan Breakdown of academic impact, for papers by Angus D. Cowan Breakdown of academic impact, for papers by Judith Gan Breakdown of academic impact, for papers by Yanping Yu Breakdown of academic impact, for papers by Shannon Telesco
Rankless by CCL
2026